Electronic Journal of General Medicine

• Al-Moundhri M, Nirmala V, Al-Mawaly K, et al. Significance of p53, Bcl-2 and Her-2/neu protein expression in Omani Arab females with breast cancer. Pathol Oncol Res 2003;9:226-31
• Yamashita H, Nishio M, Toyama T, et al. Coexistence of HER-2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res 2004;6:24-30
• Meenakshi A, Kumar RS, Ganesh V, et al. Immunohistochemical assay (IHC) to study C-erbB-2 status of breast cancer using monoclonal antibody CIBCgp185. Hum Antibodies 2003;12(4):123-7
• Diaz NM. Laboratory testing for Her2/neu in breast carcinoma: An evolving strategy to predict response to targeted therapy. Cancer Control 2001;8(5):415-8
• Hudziak RM, Lewis GD, Shalaby MR, et al. Amplified expression of the HER2/ErbB2 oncogene induces resistance to tumor necrosis factor alpha in NIH3T3 cells. Proc Natl Acad Sci USA 1988; 85(14):5102-6
• Zhou BP, Hu MC, Miller SA, et al. HER-2/neu blocks tumor necrosis factor induced apoptosis via the Akt/NF-kappa B pathway. J Biol Chem 2000;275(11): 8027-31
• Rosenblum MG, Horn SA & Cheung LH. A novel recombinant fusion toxin targeting HER-2/neu over expressing cells and containing human tumor necrosis factor. Int J Cancer 2000;88(2):267-73
• Scarff RW, Torloni H. Histological typing of breast tumors. 1968 International histological classification of tumors. World Health Organization, Geneva,no2 vol2; pp 13-20
• Hlupic L, Jakic-Razumovic J, Bozikov J, et al. Prognostic value of different factors in breast carcinoma. Tumori 2004;90(1): 112-9
• Sorli T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguishes tumor subclasses with clinical implication. PNAS 2001;98(19):10869-74
• Winters ZE, Leek RD, Bradurn MJ, et al. Cytoplasmic p21 WAF1/CIP1 expression is correlated with HER-2/neu in breast cancer and is an independent predictor of prognosis. Breast Cancer Res 2003;5: 242-9
• Salmon DJ, Clark GM, Wong SG, et al. Human breast cancer. Correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987; 235:177-82
• Ross JS, Fletcher JA. The Her-2/neu oncogene in breast cancer: Prognostic factor, prediction factor and target for therapy. Oncologist 1998;3(4):237-52
• Huang WY, Newman B, Millikan RC, et al. Risk of breast cancer according to the status of Her-2/neu oncogene amplification. Cancer epidemiology biomarkers & Prevention 2000;9:65-71
• Nieto Y, Cagnoni PJ, Nawaz S, et al. Evaluation of the predictive value of Her2/neu over expression and p53 mutations in high risk primary brest cancer patients treated with high dose chemotherapy and autologous stem cell transplantation. J Clin Oncol 2000;18(10):2070-80
• Guerra I, Algorta J, Díaz de Otazu R. Immunohistochemical prognostic index for breast cancer in young women. Molecular Pathology 2003;56:323-7
• Smith CA, Pollice AA, Gu LP et al. Correlations among p53, Her-2/neu and ras over expression and aneuploidy by multiparameter flow cytometry in human breast cancer: Evidence for a common phenotypic evolutionary pattern in infilterating ductal carcinoma. Clinical Cancer Res 2000;16:112-6
• Marks JR, Humphrey PA, Wu K, et al. Over expression of p53 and HER2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994;219(4):332-41
• Tsutsui S, Ohno S, Murakami S, et al. Prognostic significance of the coexpression of p53 protein and c-erbB2 in breast cancer. Am J Surg 2003;185(2): 165-7
• Konecny G, Pauletti G, Pegram M, et al. Quantitive associated between Her-2/neu and steroid hormone receptors-positive primary breast cancer. JNCI 2003;95(2): 142-53
• Thor A. Are patterns of Her-2/neu amplification and expression among primary and regional metastasis indicative of distance metastasis and predictive of herceptin response? JNCI 2001;93(15):1112-21
• Menard S, Frotis S, Castiglioni F, et al. HER-2 as a prognostic factor in breast cancer. Oncology 2001;61(suppl 2):67- 72
• Swede H, Moysich KB, Winston JS et al. Variation of the prognostic significance of Her-2 expression in breast cancer according to tumor size. Breast J. 2003 Mar-Apr; 9(2):98-105
• Ray A, Sharma BK, Kaur S, et al. Over expression of c-erbB2 oncoprotein and associated pathobiological factors in invasive primary breast cancer. Indian J Exp Biol 2004;42(3):253-8
• Climent MA, Segui MA, Molina R, et al. Prognostic value of HER-2/neu and p53 expression in node positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment. Breast 2001;10(1):67-77
• Sutterlin MW, Haller A, Gassel AM, et al. The correlation of c-erbB2 oncoprotein and established prognostic factors in human breast cancer. Anticancer Res 2000;20(6D):5083-8
• Korkolis DP, Tsoli E, Fouskakis D, et al. Tumor histology and stage but not p53, Her-2/neu or cathepsin-D expressions are independent prognostic factors in breast cancer patients. Anticancer Res 2004;24(3b):2061-8
• Nishikawa K, Satoh H, Hirai, A et al. alpha-Tocopheryloxy butyric acid enhances necrotic cell death in breast cancer cell treated with chemotherapy agent. Cancer lett. 2003;201(1):51-6
• Bobrow LG, Happerfield LG, Gregory WM, et al. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. J Path 1995; 176(4): 333-41
• Yagata H, Hariaga K, Suzuki M et al. Comedonecrosis is an unfavorable marker in node negative invasive breast carcinoma. Pathol Int 2003; 53(8):501-6
• Egeblad M, Jattela M. Cell death induced by TNF or serum starvation is indepent of erbB receptor signaling in MCF-7 breast carcinoma cells. Int J Cancer 2000;86(5): 617-25
• Adebamowo CA, Ogundiran A, Kang EE, et al. Somatic p53 and HER-2/neu in Nigerian breast cancer. Proc Am Clin Oncol 2003;22:885

Vancouver

Rashed MM, Ragab NM, Galal MK. THE ASSOCIATION OF HER-2/NEU OVER-EXPRESSION IN RELATION TO P53 NUCLEAR ACCUMULATION, HORMONAL RECCEPTOR STATUS AND COMMON CLINICO-PATHOLOGICAL PROGNOSTIC PARAMETERS IN A SERIES OF EGYPTIAN WOMEN WITH INVASIVE DUCTAL CARCINOMA. EUR J GEN MED. 2007;4(2):73-9. https://doi.org/10.29333/ejgm/82489

APA

Rashed, M. M., Ragab, N. M., & Galal, M. K. (2007). THE ASSOCIATION OF HER-2/NEU OVER-EXPRESSION IN RELATION TO P53 NUCLEAR ACCUMULATION, HORMONAL RECCEPTOR STATUS AND COMMON CLINICO-PATHOLOGICAL PROGNOSTIC PARAMETERS IN A SERIES OF EGYPTIAN WOMEN WITH INVASIVE DUCTAL CARCINOMA. European Journal of General Medicine, 4(2), 73-79. https://doi.org/10.29333/ejgm/82489

AMA

Rashed MM, Ragab NM, Galal MK. THE ASSOCIATION OF HER-2/NEU OVER-EXPRESSION IN RELATION TO P53 NUCLEAR ACCUMULATION, HORMONAL RECCEPTOR STATUS AND COMMON CLINICO-PATHOLOGICAL PROGNOSTIC PARAMETERS IN A SERIES OF EGYPTIAN WOMEN WITH INVASIVE DUCTAL CARCINOMA. EUR J GEN MED. 2007;4(2), 73-79. https://doi.org/10.29333/ejgm/82489

Chicago

Rashed, Mona M., Noha M. Ragab, and Manal K. Galal. "THE ASSOCIATION OF HER-2/NEU OVER-EXPRESSION IN RELATION TO P53 NUCLEAR ACCUMULATION, HORMONAL RECCEPTOR STATUS AND COMMON CLINICO-PATHOLOGICAL PROGNOSTIC PARAMETERS IN A SERIES OF EGYPTIAN WOMEN WITH INVASIVE DUCTAL CARCINOMA". European Journal of General Medicine 2007 4 no. 2 (2007): 73-79. https://doi.org/10.29333/ejgm/82489

Harvard

Rashed, M. M., Ragab, N. M., and Galal, M. K. (2007). THE ASSOCIATION OF HER-2/NEU OVER-EXPRESSION IN RELATION TO P53 NUCLEAR ACCUMULATION, HORMONAL RECCEPTOR STATUS AND COMMON CLINICO-PATHOLOGICAL PROGNOSTIC PARAMETERS IN A SERIES OF EGYPTIAN WOMEN WITH INVASIVE DUCTAL CARCINOMA. European Journal of General Medicine, 4(2), pp. 73-79. https://doi.org/10.29333/ejgm/82489

MLA

Rashed, Mona M. et al. "THE ASSOCIATION OF HER-2/NEU OVER-EXPRESSION IN RELATION TO P53 NUCLEAR ACCUMULATION, HORMONAL RECCEPTOR STATUS AND COMMON CLINICO-PATHOLOGICAL PROGNOSTIC PARAMETERS IN A SERIES OF EGYPTIAN WOMEN WITH INVASIVE DUCTAL CARCINOMA". European Journal of General Medicine, vol. 4, no. 2, 2007, pp. 73-79. https://doi.org/10.29333/ejgm/82489